Application of PD1 (programmed cell death 1)-CTLA4 (cytotoxic T lymphocyte-associated antigen-4) and/ or PDL2 (programmed cell death 1 ligand 2)-CTLA4 for preparing kit for predicting AML (acute myeloid leukemia) prognosis

A technology of PDL2-CTLA4 and PD1-CTLA4, applied in the field of biomedicine, can solve the problems that the prognosis of AML patients cannot be fully evaluated, and achieve the effects of high possibility of poor prognosis, stable method, and simple and easy method

Inactive Publication Date: 2020-05-01
JINAN UNIVERSITY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the prognostic role of PD-L1 in AML patients with certain types of mutations has been analyzed by survival curves, it is well known that ICs may be co-expressed and participate in the immunosuppressive network
There is still a lack of systematic analysis of different IC expression patterns and IC combinations to fully evaluate the prognosis of AML patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PD1 (programmed cell death 1)-CTLA4 (cytotoxic T lymphocyte-associated antigen-4) and/ or PDL2 (programmed cell death 1 ligand 2)-CTLA4 for preparing kit for predicting AML (acute myeloid leukemia) prognosis
  • Application of PD1 (programmed cell death 1)-CTLA4 (cytotoxic T lymphocyte-associated antigen-4) and/ or PDL2 (programmed cell death 1 ligand 2)-CTLA4 for preparing kit for predicting AML (acute myeloid leukemia) prognosis
  • Application of PD1 (programmed cell death 1)-CTLA4 (cytotoxic T lymphocyte-associated antigen-4) and/ or PDL2 (programmed cell death 1 ligand 2)-CTLA4 for preparing kit for predicting AML (acute myeloid leukemia) prognosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] (1) Bone marrow was collected under the premise of signing the informed consent form with the patient. Bone marrow samples from 62 cases of first-onset AML and 12 cases of healthy adults were collected from the Department of Hematology, Guangzhou First People's Hospital. All samples were taken from the bone marrow anticoagulated with heparin at the time of admission. This part of the research protocol has been approved by the ethics committee of the unit. At the same time, clinical data such as survival time and survival status of AML patients were collected (as shown in Table 1).

[0065] (2) Isolation of mononuclear cells in bone marrow. Take 4mL of lymphocyte separation medium (Ficoll, density 1.077) and add it into a 15mL centrifuge tube, spread the diluted anticoagulated bone marrow specimen suspension on the separation medium, and centrifuge at 1500rpm for 15 minutes in a horizontal centrifuge. Transfer the single nuclear layer in the middle to another 15mL centr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of a PD1 (programmed cell death 1)-CTLA4 (cytotoxic T lymphocyte-associated antigen-4) and / or PDL2 (programmed cell death 1 ligand 2)-CTLA4 for preparing a kit forpredicting AML (acute myeloid leukemia) prognosis. On the basis of the invention, an inventor discovers PD1 and CTLA4 in the bone marrow of an AML patient for the first time, the expression situationof the PLD2 and the CTLA4, and the prognosis correlation of an AML patient. When a simultaneous expression ratio of the PD1 to the CTLA4 and / or the PDL2 to the CTLA4 is high, a result indicates thata possibility of poor AML patient clinical prognosis is large. The combination of the PD1 and the CTLA4 and / or a combined expression ratio of the PDL2 to the CTLA4 has an important guidance meaning for making a plan for the prognostic judgment and clinic treatment scheme of the AML patient, more clinic prognosis research data is provided for the AML patient to realize the combined application ofimmune checkpoint inhibitors PD1-CTLA4 and PDL2-CTLA4, and the invention has a wide application prospect.

Description

technical field [0001] The invention belongs to the field of biomedicine, and particularly relates to the application of PD1-CTLA4 and / or PDL2-CTLA4 in the preparation of a kit for predicting AML prognosis. Background technique [0002] Acute myeloid leukemia (AML) is the most common type of adult leukemia, with an incidence rate of 3.7 / 100,000. The prognosis of AML patients deteriorates with age, and the 5-year survival rate of patients over 60 years old is less than 10%. AML is caused by multiple genetic factors, environmental changes and their complex interactions. According to the cytogenetic and molecular biological characteristics of patients, they can be divided into three categories: low risk, intermediate risk and high risk. Although different classes of AML patients benefit from chemotherapy and hematopoietic stem cell transplantation, the prognosis of these patients varies widely. [0003] The variable prognosis of AML patients suggests that other key factors, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12Q1/6851
CPCC12Q1/6886C12Q1/6851C12Q2600/118C12Q2600/158C12Q2600/166C12Q2531/113C12Q2545/101C12Q2561/113
Inventor 李扬秋陈存特梁朝峰曾成武陈少华王彩霞
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap